Latest Biochemistry of Alzheimer's disease Stories
By Lauran Neergaard WASHINGTON - Scientists for the first time have peered into people's brains to directly measure the ebb and flow of a substance notorious for its role in Alzheimer's disease.
By LAURAN NEERGAARD By Lauran Neergaard The Associated Press WASHINGTON Scientists for the first time have peered into people's brains to directly measure the ebb and flow of a substance notorious for its role in Alzheimer's disease.
ProteoTech has completed regulatory investigational new drug requirements and has received clearance from the FDA to initiate its Phase I human clinical trial on Exebryl-1, a small molecule drug targeting toxic beta-amyloid protein accumulation for the treatment of Alzheimer's disease.
KIRKLAND, Wash., Aug. 7 /PRNewswire/ -- ProteoTech Inc.
By John Fauber, Milwaukee Journal Sentinel Jul. 30--CHICAGO -- The first Alzheimer's drug that actually may arrest the progress of the disease showed promising results in early clinical trial research presented Tuesday in Chicago.
Researchers at Scotland's University of Aberdeen say a new drug they've developed holds great promise in slowing the progression of Alzheimer's disease.
Pfizer, Inc announced today that it will present nine abstracts from its Alzheimer's disease (AD) research and development program, including three on the two promising investigational therapies in the early stages of development, at the 2008 Alzheimer's Association International Conference on Alzheimer's Disease (ICAD) in Chicago, July 26-31.
U.S. scientists say the protein neprilysin can reduce plaque formation and neuron death associated with Alzheimer's disease, but at the expense of lifespan. Thomas Jefferson University researchers said the buildup of amyloid-beta protein plaques within the brain is a hallmark of Alzheimer's.
By Randolph E. Schmid Associated Press WASHINGTON -- Researchers have uncovered a new clue to the cause of Alzheimer's disease. The brains of people with the memory-robbing form of dementia are cluttered with a plaque made up of beta-amyloid, a sticky protein.
Researchers from Harvard Medical School have made what they believe to be a key discovery in the cause of Alzheimerâ€™s disease. Their research found that people who suffer from a form of dementia that affects memory have a certain type of plaque in their brains. The plaque is made up of a sticky protein known as beta-amyloid.
- A trick or prank.